ANAB – anaptysbio, inc. (US:NASDAQ)
Stock Stats
News
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Wells Fargo & Company from $40.00 to $51.00. They now have an "overweight" rating on the stock.
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Truist says AnaptysBio handing of placebo ‘raise doubt' about Phase 2 RA data [Yahoo! Finance]
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Fairmount Funds Management LLC
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Frazier Life Sciences Public Fund, L.P.
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: Frazier Life Sciences Public Fund, L.P.
Form 8-K ANAPTYSBIO, INC For: Feb 12
Form SCHEDULE 13G/A ANAPTYSBIO, INC Filed by: BlackRock, Inc.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.